Inga-Lill Andersson is a senior European patent attorney specialising in the fields of chemistry and biotechnology, with a particular focus on protein chemistry, pharmaceutical chemistry, biochemistry and implant technology.
In her daily work, Ms Andersson engages in all types of patent-related issue encompassing infringement and validity, such as patentability evaluations, drafting and prosecution of patent applications, due diligence investigations and freedom-to-operate analyses.
Ms Andersson has comprehensive experience of oppositions and appeals before the European Patent Office (EPO). She also completed an internship at a Technical Board of Appeal at the EPO’s headquarters in Munich. Further, Ms Andersson has participated extensively in a number of national litigation procedures, at both first and second instance. Ms Andersson also has a Centre for International Intellectual Property Studies diploma in European patent litigation from Strasbourg University.
Ms Andersson has lectured at numerous continuing legal education seminars in the United States, and is a frequent author of articles on European patent law and practice.
Ms Andersson led the work of Awapatent AB’s specialist group for life science-based inventions for seven years and is now team manager of the chemistry team in Stockholm. In 2013 she was one of four experienced consultants responsible for opening a new Awapatent branch office in Uppsala, a renowned region for biotechnological research.
Before joining Awapatent in 2000, Ms Andersson worked as an analytical chemist at AstraZeneca R&D.
PO Box 45086
Stockholm 104 30
Life sciences patent strategies in Europe
IP in the life sciences industries 2009
The European market can be a daunting one, due to the lack of a unified patent system. However, life sciences companies can employ a number of tactics in order to arrive at a successful IP strategy for patent protection
Register for more free content
- Read more IAM blogs and articles
- Receive the editor's weekly review by email